Health News from Medical News Today: Low Cost Trumps Effectiveness In PrEP Acceptance

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Low Cost Trumps Effectiveness In PrEP Acceptance 3 Jun 2011, 6:00 pm In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent. While the findings are reason for great optimism, researchers say it is now important to understand the factors that could influence the public's willingness to use the drug in this way, known as pre-exposure prophylaxis, or PrEP. Scientists, health authorities and policymakers are currently debating the pros and cons of PrEP in the U.S. and around the world... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.